Evidence map›Paper›PMID 41850246›Full record

ArticleCell reports. Medicine2026

Inhibition of MAPK p38α overcomes the cancer immunosurveillance defect caused by FPR1 loss-of-function mutation.

Yuhong Pan, Liwei Zhao, Jiani Liu, Misha Mao, Ai-Ling Tian, Julie Le Naour, Sarah Adriana Scuderi, Hui Pan, Flora Doffe, Donal Naylor and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yuhong PanMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institute, Villejuif, France; Centre de Recherche des Cordeliers, Equipe Labellisée Par La Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris, France; Faculté de Médecine, Université Paris-Saclay, Paris, France; Institute of Veterinary Medicine and Immunology, Sichuan Agricultural University, Chengdu, China; Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu, China.
Liwei ZhaoMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institute, Villejuif, France; Centre de Recherche des Cordeliers, Equipe Labellisée Par La Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris, France.
Jiani LiuMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institute, Villejuif, France; Centre de Recherche des Cordeliers, Equipe Labellisée Par La Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris, France.
Misha MaoMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institute, Villejuif, France; Centre de Recherche des Cordeliers, Equipe Labellisée Par La Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris, France; Faculté de Médecine, Université Paris-Saclay, Paris, France.
Ai-Ling TianMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institute, Villejuif, France; Centre de Recherche des Cordeliers, Equipe Labellisée Par La Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris, France.
Julie Le NaourMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institute, Villejuif, France; Centre de Recherche des Cordeliers, Equipe Labellisée Par La Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris, France.
Sarah Adriana ScuderiMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institute, Villejuif, France; Centre de Recherche des Cordeliers, Equipe Labellisée Par La Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris, France; Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy.
Hui PanMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institute, Villejuif, France; Centre de Recherche des Cordeliers, Equipe Labellisée Par La Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris, France; Faculté de Médecine, Université Paris-Saclay, Paris, France.
Flora DoffeMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institute, Villejuif, France; Centre de Recherche des Cordeliers, Equipe Labellisée Par La Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris, France.
Donal NaylorMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institute, Villejuif, France; Centre de Recherche des Cordeliers, Equipe Labellisée Par La Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris, France; Faculté de Médecine, Université Paris-Saclay, Paris, France.
Hannah FelchleMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institute, Villejuif, France; Centre de Recherche des Cordeliers, Equipe Labellisée Par La Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris, France; Technical University of Munich (TUM), TUM School of Medicine and Health, Klinikum Rechts der Isar, Department of Radiation Oncology, Munich, Germany.
Marie ValetMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institute, Villejuif, France; Centre de Recherche des Cordeliers, Equipe Labellisée Par La Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris, France; Faculté de Médecine, Université Paris-Saclay, Paris, France.
Maria Chiara MaiuriMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institute, Villejuif, France; Centre de Recherche des Cordeliers, Equipe Labellisée Par La Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris, France; Department of Molecular Medicine and Medical Biotechnologies, University of Napoli Federico II, Napoli, Italy.
Renyong JiaInstitute of Veterinary Medicine and Immunology, Sichuan Agricultural University, Chengdu, China; Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu, China.
Yuting MaNational Key Laboratory of Immunity and Inflammation, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, China; Collaborative Innovation Center for Cancer Personalized Medicine & Gusu School, Nanjing Medical University, Nanjing, China.
Laurence ZitvogelINSERM U1015, Equipe Labellisée-Ligue Nationale Contre le Cancer, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France; Department of Biology, Center of Clinical Investigations in Biotherapies of Cancer (CICBT) BIOTHERIS, Villejuif, France.
Oliver KeppMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institute, Villejuif, France; Centre de Recherche des Cordeliers, Equipe Labellisée Par La Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris, France. Electronic address: oliver.kepp@gustaveroussy.fr.
Peng LiuMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institute, Villejuif, France; Centre de Recherche des Cordeliers, Equipe Labellisée Par La Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris, France. Electronic address: peng.liu@inserm.fr.
Guido KroemerMetabolomics and Cell Biology Platforms, UMS AMMICa, Gustave Roussy Institute, Villejuif, France; Centre de Recherche des Cordeliers, Equipe Labellisée Par La Ligue Contre le Cancer, INSERM U1138, Université Paris Cité, Sorbonne Université, Paris, France; Institut Du Cancer Paris CARPEM, Department of Biology, Hôpital Européen Georges Pompidou, AP-HP, Paris, France. Electronic address: kroemer@orange.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A loss-of-function polymorphism affecting the N-terminus of human formyl peptide receptor 1 (FPR1) leads to a single amino acid exchange that compromises dendritic cell (DC) migration, weakens immunosurveillance, and triggers the precocious manifestation of epithelial cancers. We present a mouse model bearing a human-mimetic mutation in FPR1 that causes the same DC defect as that observed in Fpr1 knockout animals. Genetic and pharmacological screening performed on type 1 conventional DCs (cDC1) expressing mutated FPR1 leads to the discovery that inhibitors of mitogen-activated protein kinase (MAPK) p38α correct this FPR1 defect. Small-molecule MAPK p38α inhibitors are able to restore the function of FPR1 knockout or mutated cDC1 in vitro and in vivo, hence correcting defective responses to anticancer chemotherapy or immune checkpoint blockade in mouse models. Pharmacological MAPK p38α inhibition also normalizes accelerated colorectal carcinogenesis in mice bearing an immune system affected by the absence or mutation of FPR1.

Indexed as

Immunologic SurveillanceLoss of Function MutationMitogen-Activated Protein Kinase 14NeoplasmsReceptors, Formyl PeptideAnimalsDendritic CellsHumansMiceMice, Inbred C57BLMice, KnockoutMonitoring, ImmunologicFPR1 protein, humanFpr1 protein, mouseMitogen-Activated Protein Kinase 14Receptors, Formyl Peptideimmunostimulationimmunotherapyinborn error of immunitymyeloid cellspattern recognition receptorsPD-1 blockadeT cells

Identifiers

PMID41850246
PMCPMC13006421

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.